CD274 and cancer: In a co-culture system of HLA-matched iPSC-derived CD8+ T cells and cancer cells, the secreted PD-L1 variants were shown to inhibit the activation and proliferation of T cells, ultimately leading to reduced efficacy of immune checkpoint inhibitor therapy.